JP Morgan Private Capital, JP Morgan’s venture capital and growth equity investment team has held the final close of 270 Life Sciences Private Capital Fund I, above its $500m target.
LSPCF received commitments from institutional allocators, strategic corporate partners, family offices and HNWIs across North America, Europe, the Middle East and Asia, as well as JPMorgan Chase & Co. The fund close was led by CIO Stephen Squinto and Managing Partner Gaurav Gupta.
LSPCF invests in private biotechnology companies spanning cardiometabolic disease, oncology, immunology and genetic medicines.
Source:Private Equity Wire
Can’t stop reading? Read more
Carlyle edges ahead in €6bn pursuit of BASF’s coatings division
Carlyle edges ahead in €6bn pursuit of BASF’s coatings division Carlyle Group has emerged as the...
CVC expands US footprint with $1.75bn acquisition of data-driven insurer Bamboo
CVC expands US footprint with $1.75bn acquisition of data-driven insurer Bamboo CVC Capital...
Bain Capital closes $14bn flagship buyout fund, topping $10bn target
Bain Capital closes $14bn flagship buyout fund, topping $10bn target Bain Capital has completed...
